CTI Life Sciences Fund L.P.
CTI Life Sciences Fund L.P. is a Montreal-based venture capital firm established in 2006, specializing in investments within the life sciences sector. The firm focuses on pre-clinical to proof-of-concept and proof-of-concept to Phase III stages of pharmaceutical development, primarily targeting biotechnology, medical technology, biopharmaceuticals, drug enabling technology, and medical devices. CTI Life Sciences typically invests between $5 million and $15 million for initial funding in pre-clinical projects, with post-money valuations ranging from $15 million to $35 million. For later-stage investments, it commits between $25 million and $50 million, with post-money valuations from $75 million to $150 million. The firm seeks to exit its investments through mergers and acquisitions, primarily concentrating on companies located in the United States and Canada, particularly in Quebec. Currently, CTI Life Sciences manages assets totaling approximately $245 million.
DalCor Pharmaceuticals specializes in precision medicine aimed at treating cardiovascular diseases by tailoring therapies to individual patients based on their genetic profiles. The company's primary product, dalcetrapib, is a cholesterol ester transfer protein inhibitor designed to mitigate residual cardiovascular risk in patients with a specific ADCY9 genetic profile. This approach is supported by pharmacogenomic research indicating that patients with acute coronary syndrome who possess a particular genetic variant experience a significant reduction in cardiovascular events when treated with dalcetrapib compared to placebo. Founded in 2015, DalCor has established its headquarters in Montreal, Canada, with additional offices in Sarasota, Florida; Zug, Switzerland; and Leatherhead, United Kingdom. The company has secured exclusive worldwide rights to dalcetrapib and the associated ADCY9 genetic marker from Roche, allowing it to focus on enhancing treatment outcomes for genetically targeted patients.
Enobia Pharma focuses on developing therapies for serious genetic bone disorders that currently lack approved treatments. The company specifically targets conditions such as hypophosphatasia (HPP), a rare metabolic disorder that affects bone mineralization and can lead to severe skeletal deformities and other health complications. Through its innovative research and development efforts, Enobia aims to provide effective solutions for patients suffering from these debilitating conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.